Mechanisms for Behavior Change and Maintenance of Treatment for CKD Comorbid Depression

CKD 共病抑郁症的行为改变和维持治疗机制

基本信息

  • 批准号:
    10667222
  • 负责人:
  • 金额:
    $ 42.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-04-01 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract The purpose of this application is to understand why interventions for the treatment of Major Depressive Disorder (MDD) work or do not work initially and over time in patients with Chronic Kidney Disease (CKD). This project will add assessments to my ongoing NIH R01-funded study (R01DK124379-05), Combination of Novel Therapies for CKD Comorbid Depression, to help illuminate mechanisms of action mediating response to treatment; facilitators and barriers to adoption of treatment; and maintenance of treatment response. We will collect complimentary data that will use information from the subset of participants who have completed the parent study to investigate mechanisms for depression treatment effect, or lack thereof, and also identify the maintenance of treatment effect beyond the active intervention period in those who initially have remission in depression after 8 weeks of treatment. In the parent R01 study, we are currently comparing the efficacy of two 16-week strategies vs. control for treatment of MDD starting with (1) Behavioral Activation Therapy (BAT) or (2) bupropion drug therapy, each augmented to a combination of both in non-remitters after 8 weeks. We will engage the subset of participants that have completed the parent trial to: Aim 1. Identify mechanisms of action of intervention effect, vs. lack thereof, by identifying candidate inflammatory mediators/moderators of MDD treatment response in CKD patients. We will use (a) RNA-Sequencing of whole blood gene expression and (b) plasma inflammatory biomarkers from frozen samples that have already been collected at baseline and at week 8 from patients who completed at least 8 weeks from the parent study (N =76). We will evaluate whether there is a modification from baseline in candidate innate immune activation/inflammatory pathways through targeted whole genomic transcriptional profiling and plasma biomarkers in (a) depression remitters (defined as Quick Inventory of Depressive Symptomatology score - QIDS-SR ≤5) vs. non-remitters; and (b) responders to treatment (defined as a decrease in the QIDS-SR score by ≥3 points from baseline) vs. non-responders to treatment. Aim 2. Assess underlying facilitators of or barriers to behavior adoption, in this case adherence to MDD treatment interventions (drug by pill count and BAT teletherapy sessions), in patients with CKD. We will conduct focus groups in 50 participants who have finished the 16-week trial to gather data on participants’ experiences, barriers to and facilitators of intervention engagement and adherence, and perceived benefits of the intervention. Aim 3. Assess maintenance of MDD treatment response over time, beyond the 16-week active intervention period (N =50), in remitters vs. non-remitters at 8 weeks, by assessing improvement in patient-centered outcomes of (a) depressive symptoms; (b) fatigue; (c) sleep; (d) overall functioning. This application corresponds with my parent R01’s scope and timeline and the purpose and requirements of the Office of Behavioral and Social Sciences Research. The aims will not interfere and do not overlap with the original scope of the parent R01.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Susan Hedayati其他文献

Susan Hedayati的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Susan Hedayati', 18)}}的其他基金

Blood Biomarkers Associated with Adverse Outcomes in Heart Failure
与心力衰竭不良后果相关的血液生物标志物
  • 批准号:
    10650694
  • 财政年份:
    2023
  • 资助金额:
    $ 42.6万
  • 项目类别:
University of Texas Southwestern - Stimulating Access to Research in Residency (UT-StARR) Program
德克萨斯大学西南分校 - 促进住院医师研究 (UT-StARR) 计划
  • 批准号:
    10318221
  • 财政年份:
    2021
  • 资助金额:
    $ 42.6万
  • 项目类别:
Combination of Novel Therapies for CKD Comorbid Depression (CONCORD)
CKD 共病抑郁症的新疗法组合 (CONCORD)
  • 批准号:
    10640205
  • 财政年份:
    2020
  • 资助金额:
    $ 42.6万
  • 项目类别:
Combination of Novel Therapies for CKD Comorbid Depression (CONCORD)
CKD 共病抑郁症的新疗法组合 (CONCORD)
  • 批准号:
    10404490
  • 财政年份:
    2020
  • 资助金额:
    $ 42.6万
  • 项目类别:
Randomized trial of sertraline treatment of depression in Chronic Kidney Disease
舍曲林治疗慢性肾脏病抑郁症的随机试验
  • 批准号:
    8212573
  • 财政年份:
    2011
  • 资助金额:
    $ 42.6万
  • 项目类别:
Randomized trial of sertraline treatment of depression in Chronic Kidney Disease
舍曲林治疗慢性肾脏病抑郁症的随机试验
  • 批准号:
    8792383
  • 财政年份:
    2011
  • 资助金额:
    $ 42.6万
  • 项目类别:
Randomized trial of sertraline treatment of depression in Chronic Kidney Disease
舍曲林治疗慢性肾脏病抑郁症的随机试验
  • 批准号:
    8607181
  • 财政年份:
    2011
  • 资助金额:
    $ 42.6万
  • 项目类别:
Randomized trial of sertraline treatment of depression in Chronic Kidney Disease
舍曲林治疗慢性肾脏病抑郁症的随机试验
  • 批准号:
    8423402
  • 财政年份:
    2011
  • 资助金额:
    $ 42.6万
  • 项目类别:
Randomized trial of sertraline treatment of depression in Chronic Kidney Disease
舍曲林治疗慢性肾脏病抑郁症的随机试验
  • 批准号:
    8042121
  • 财政年份:
    2011
  • 资助金额:
    $ 42.6万
  • 项目类别:
Randomized trial of sertraline treatment of depression in Chronic Kidney Disease
舍曲林治疗慢性肾脏病抑郁症的随机试验
  • 批准号:
    7787841
  • 财政年份:
    2009
  • 资助金额:
    $ 42.6万
  • 项目类别:

相似海外基金

An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 42.6万
  • 项目类别:
    Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 42.6万
  • 项目类别:
    Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 42.6万
  • 项目类别:
    Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 42.6万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 42.6万
  • 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 42.6万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 42.6万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 42.6万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 42.6万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 42.6万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了